Table 1.
Descriptive characteristics of the studies included
| Study ID | Design | Country | Site | NOS/Jaded score | Age (I vs. C) | N (used GC vs. didn't use GC) | Gender Male/Total (I vs. C) |
|---|---|---|---|---|---|---|---|
| Guan | Cohort | China | Multi- center | 5 |
Severe: 52.0 (40.0–65.0) Nonsevere: 45.0 (34.0–57.0) |
204; 895 | Severe: 100/173 Nonsevere: 537/923 |
| Yang | Cohort | China | Single center | 6 |
Survivors: 51·9 (12·9) Nonsurvivors: 64·6 (11·2) |
30; 22 | Survivors: 14/20 Nonsurvivors: 21/32 |
| Zhou | Cohort | China | Two centers | 6 |
Survivors: 52·0 (45·0–58·0) Nonsurvivors: 69·0 (63·0–76·0) |
57; 134 | Survivors: 81/137 Nonsurvivors: 38/54 |
| Cao | Cohort | China | Single center | 6 |
Survivors: 53 (47-66) Nonsurvivors: 72 (63-81) |
51; 51 | Survivors: 40/85 Nonsurvivors: 13/17 |
| Salacup | Cohort | USA | Single center | 6 |
Survivors: 64.08±15.07 Nonsurvivors: 73.15±11.01 |
55; 187 | Survivors: 96/190 Nonsurvivors: 27/52 |
| Li | Cohort | China | Single center | 6 |
Survivors: 62 (53-70) Nonsurvivors: 71 (69-77) |
70; 4 | Survivors: 33/60 Nonsurvivors: 11/14 |
| Zha | Cohort | China | Two centers | 8 |
Corticosteroid: 53 (36–57) Noncorticosteroid: 37 (27–52) |
11; 20 |
Corticosteroid: 8/11 Noncorticosteroid: 12/20 |
| Wang | Cohort | China | Single center | 8 |
Corticosteroid: 54(48,63) Noncorticosteroid: 53(48,63) |
26; 20 |
Corticosteroid: 16/26 Noncorticosteroid: 10/20 |
| Gong | Cohort | China | Single center | 4 |
Corticosteroid: 38.22 ± 8.95 Noncorticosteroid: 33.75 ± 7.80 |
18; 16 |
Corticosteroid: 11/18 Noncorticosteroid: 11/16 |
| Cruz | Cohort | Spain | Single center | 7 |
Corticosteroid: 65.4 (12.9) Noncorticosteroid: 68.1 (15.7) |
396; 67 | Corticosteroid: 276/396 Noncorticosteroid: 41/67 |
| Fang | Cohort | China | Single center | 7 |
Corticosteroid: General group − 40.2±12.6. Severe group − 60.6±13.6 Noncorticosteroid: General group -− 39.9±15.5. Severe group − 54.3±15.4 |
25; 53 |
Corticosteroid: General group—5/9. Severe group—12/16 Noncorticosteroid: General group—22/46. Severe group—5/7 |
| Wu | Cohort | China | Single center | 6 |
Without ARDS: 48.0 (40.0–54.0) With ARDS: 58.5 (50.0–69.0) |
62; 139 |
Without ARDS: 68/117 With ARDS: 60/84 |
| Shang | Cohort | China | Multi- center | 6 |
Survivors: Common − 46·0(33·0–56·0). Severe – 50.0(38·0–60.0) Death: 67.0(61.0–77.0) |
196; 220 |
Survivors: Common—89/226. Severe - 77/139 Death: 31/51 |
| Xu | Cohort | China | Two centers | 6 |
< 15 days to viral clearance: 48 (34, 61) 15 days to viral clearance: 54.5 (45, 63) |
64/49 | < 15 days to viral clearance: 15/37 > 15 days to viral clearance: 51/76 |